Skip to content
Oncology Research Hub

Baltimore, Maryland

Cancer clinical trials in Baltimore, MD

223 cancer studies are recruiting participants at sites in Baltimore as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Baltimore at a glance

  • 223 studies are recruiting at a site in Baltimore.
  • By phase: Early Phase 1 (3), Phase 1 (25), Phase 1/2 (22), Phase 2 (52), Phase 2/3 (4), Phase 3 (67), No phase (18), Observational (32). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (102), university, hospital or other (102), government (19).
  • By research area: Lung Cancer (67), Breast Cancer (52), Prostate Cancer (41), Lymphoma (37), Pancreatic Cancer (21), Melanoma (5).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Baltimore

Basic details from each study's public record (the 30 most recently updated of 223). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    Johns Hopkins Kimmel Cancer Center
    Registry record
    NCT05696626 · updated
  2. Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT03606967 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT05564377 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Mercy Medical Center · Sinai Hospital of Baltimore
    Registry record
    NCT06058377 · updated
  5. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study site
    Sidney Kimmel Comprehensive Cancer Center
    Registry record
    NCT06638307 · updated
  6. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    MedStar Franklin Square Medical Center ( Site 0031) · MedStar Good Samaritan Hospital ( Site 0079)
    Registry record
    NCT06841354 · updated
  7. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Mercy Medical Center - Baltimore ( Site 0015)
    Registry record
    NCT06966700 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Lung cancer studies recruiting in Baltimore

  1. Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Teligene US
    Study site
    University of Maryland Medical Center
    Registry record
    NCT05168566 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT06287775 · updated
  3. Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    MedStar Franklin Square Medical Center ( Site 0033)
    Registry record
    NCT06780098 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Greater Baltimore Medical Center · Johns Hopkins University/Sidney Kimmel Cancer Center · Kaiser Permanente-Woodlawn Medical Center
    Registry record
    NCT04267848 · updated
  5. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT06096844 · updated
  6. Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    OSE Immunotherapeutics
    Study site
    Ascension Saint Agnes Hospital
    Registry record
    NCT06472245 · updated
  7. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT06498635 · updated
  8. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Johns Hopkins University
    Registry record
    NCT07020221 · updated
  9. Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07291037 · updated
  10. DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    University of Maryland School of Medicine
    Registry record
    NCT07472517 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Prostate cancer studies recruiting in Baltimore

  1. Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT04423211 · updated
  2. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Baltimore Veterans Affairs Medical Center ( Site 0069) · Greenebaum Comprehensive Cancer Center ( Site 0049)
    Registry record
    NCT06136624 · updated
  3. Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

    • Phase 2
    • Ages 18 and older
    • Male participants
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT05691465 · updated
  4. Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe

    • Phase 1
    • Ages 40 to 75
    • Male participants
    Sponsor
    Johns Hopkins University
    Study site
    Johns Hopkins Hospital
    Registry record
    NCT07271017 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Lymphoma studies recruiting in Baltimore

  1. Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    Eastern Cooperative Oncology Group
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT06724237 · updated
  2. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT04269902 · updated
  3. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore
    Registry record
    NCT04546399 · updated
  4. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Johns Hopkins University/Sidney Kimmel Cancer Center · Sinai Hospital of Baltimore · University of Maryland/Greenebaum Cancer Center
    Registry record
    NCT05675410 · updated
  5. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT06337318 · updated
  6. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Johns Hopkins University/Sidney Kimmel Cancer Center
    Registry record
    NCT07003295 · updated
  7. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study site
    John Hopkins University
    Registry record
    NCT05384626 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Baltimore, MD on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Baltimore

  1. Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

    • Phase 2
    • Ages 12 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108)
    Registry record
    NCT04924075 · updated
  2. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Johns Hopkins University
    Registry record
    NCT07644559 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Baltimore, MD on ClinicalTrials.gov.

Ask about studies near Baltimore

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Maryland

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call